Even after the pandemic, various new infectious diseases continue to emerge, posing ongoing viral threats that demand robust ...

MPox is endemic in DRC, and has continued to cause large numbers of cases in the WHO African Region. In April, 2025, the WHO has restated that MPox continues to be a Public Health Emergency of ...

Immunoengineering, which has been beneficial to other medical specialties, could be used in the infectious diseases field to ...

The kissing disease affects 90% of adults and could explain your fatigue and brain fog. Discover how Epstein-Barr virus might ...

Most vaccines—and boosters—are injected directly into muscle tissue, usually in the upper arm, to kickstart the body's immune ...

New research by scientists at the University of Toronto and the Structural Genomics Consortium has deepened our understanding ...

AVI-4303, which is a C5 benzotriazole analog, exhibited ten-fold higher potency than AVI-3318. Comparatively, N1 propargyl ...

Dr. Kate Knobil joins the biotech as it looks to combat a viral infection that can be dangerous to patients with the lung ...

Clinical pipeline: 67 distinct antiviral compounds are currently in active clinical development, with 22 approved compounds ...

Announcing a new publication for Acta Materia Medica journal. The HIV-1 capsid protein (CA) plays a crucial role in viral ...

BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the successful completion of the dose optimization of its ...